Study type:
Study number:
Type of Stem Cell Treatment:
Allogeneic
Diseases:
Acute Myeloid Leukaemia (AML)
Short title:
Primary objective:
The primary end points are: overall survival
Secondary end points are: progression-free survival, non-relapse mortality, incidence of relapse
Secondary end points are: progression-free survival, non-relapse mortality, incidence of relapse
Key inclusion criteria:
Country:
Principal investigator:
Akshay Sharma
EBMT Study coordinator:
Arnaud Dalissier
Study coordinator email:
arnaud.dalissier@upmc.fr